Ana Rita Álvaro

Ana Rita Álvaro

Auto-generated profile, based on publicly available information

Ana Rita Álvaro

CNC - UC- Centre for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Trends in Molecular Medicine
Verified
Journal Article
Closed access
LGLaetitia Gaspar
Laetitia Gaspar
AÁAna Rita Álvaro
Ana Rita Álvaro
JMJoaquim Moita
Joaquim Moita
CCCláudia Cavadas
Cláudia Cavadas

16 March 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CACélia A. Aveleira
Célia A. Aveleira
MBMariana Botelho
Mariana Botelho
SCSara Carmo-Silva
Sara Carmo-Silva
JPJorge F. Pascoal
Jorge F. Pascoal
MMMarisa Ferreira Marques
Marisa Ferreira Marques
CCCláudia Cavadas
Cláudia Cavadas
Aging is characterized by autophagy impairment that contributes to age-related disease aggravation. Moreover, it was described that the hypothalamus is a critical brain area for whole-body aging development and has impact on lifespan. Neuropeptide Y (NPY) is one of the major neuropeptides present in the hypothalamus, and it has been shown that, in aged animals, the hypothalamic NPY levels decrease. Because caloric restriction (CR) delays aging, at least in part, by stimulating autophagy, and also increases hypothalamic NPY levels, we hypothesized that NPY could have a relevant role on autophagy modulation in the hypothalamus. Therefore, the aim of this study was to investigate the role of NPY on autophagy in the hypothalamus. Using both hypothalamic neuronal in vitro models and mice overexpressing NPY in the hypothalamus, we observed that NPY stimulates autophagy in the hypothalamus. Mechanistically, in rodent hypothalamic neurons, NPY increases autophagy through the activation of NPY Y1 and Y5 receptors, and this effect is tightly associated with the concerted activation of PI3K, MEK/ERK, and PKA signaling pathways. Modulation of hypothalamic NPY levels may be considered a potential strategy to produce protective effects against hypothalamic impairments associated with age and to delay aging.

16 May 2013 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
ASA Santos-Carvalho
A Santos-Carvalho
FEF Elvas
F Elvas
AÁA R Álvaro
A R Álvaro
António Francisco AmbrósioAntónio Francisco Ambrósio
António Francisco Ambrósio
CCCláudia Cavadas
Cláudia Cavadas
It has been claimed that glutamate excitotoxicity might have a role in the pathogenesis of several retinal degenerative diseases, including glaucoma and diabetic retinopathy. Neuropeptide Y (NPY) has neuroprotective properties against excitotoxicity in the hippocampus, through the activation of Y1, Y2 and/or Y5 receptors. The principal objective of this study is to investigate the potential protective role of NPY against glutamate-induced toxicity in rat retinal cells (in vitro and in an animal model), unraveling the NPY receptors and intracellular mechanisms involved. Rat retinal neural cell cultures were prepared from newborn Wistar rats (P3-P5) and exposed to glutamate (500 μM) for 24 h. Necrotic cell death was evaluated by propidium iodide (PI) assay and apoptotic cell death using TUNEL and caspase-3 assays. The cell types present in culture were identified by immunocytochemistry. The involvement of NPY receptors was assessed using selective agonists and antagonists. Pre-treatment of cells with NPY (100 nM) inhibited both necrotic cell death (PI-positive cells) and apoptotic cell death (TUNEL-positive cells and caspase 3-positive cells) triggered by glutamate, with the neurons being the cells most strongly affected. The activation of NPY Y2, Y4 and Y5 receptors inhibited necrotic cell death, while apoptotic cell death was only prevented by the activation of NPY Y5 receptor. Moreover, NPY neuroprotective effect was mediated by the activation of PKA and p38K. In the animal model, NPY (2.35 nmol) was intravitreally injected 2 h before glutamate (500 nmol) injection into the vitreous. The protective role of NPY was assessed 24 h after glutamate (or saline) injection by TUNEL assay and Brn3a (marker of ganglion cells) immunohistochemistry. NPY inhibited the increase in the number of TUNEL-positive cells and the decrease in the number of Brn3a-positive cells induced by glutamate. In conclusion, NPY and NPY receptors can be considered potential targets to treat retinal degenerative diseases, such as glaucoma and diabetic retinopathy.

16 May 2019 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
LGLaetitia Gaspar
Laetitia Gaspar
AÁAna Rita Álvaro
Ana Rita Álvaro
SCSara Carmo‐Silva
Sara Carmo‐Silva
Alexandrina Ferreira MendesAlexandrina Ferreira Mendes
Alexandrina Ferreira Mendes
ARAngela Relógio
Angela Relógio
CCCláudia Cavadas
Cláudia Cavadas
In mammals, most molecular and cellular processes show circadian changes, leading to daily variations in physiology and ultimately in behaviour. Such daily variations induce a temporal coordination of processes that is essential to ensure homeostasis and health. Thus, it is of no surprise that pharmacokinetics (PK) and pharmacodynamics (PD) of many drugs are also subject to circadian variations, profoundly affecting their efficacy and tolerability. Understanding how circadian rhythms influence drug PK, PD, and toxicity might significantly improve treatment efficacy and decrease related side effects. Therefore, it is essential to take circadian variations into account and to determine circadian parameters in pharmacological studies, especially when drugs have a short half‐life or target rhythmic processes. This review provides an overview of the current knowledge on circadian rhythms and their relevance to the field of pharmacology. Methodologies to evaluate circadian rhythms in vitro, in rodent models and in humans, from experimental to computational approaches, are described and discussed. Lastly, we aim at alerting the scientific, medical, and regulatory communities to the relevance of the physiological time, as a key parameter to be considered when designing pharmacological studies. This will eventually lead to more successful preclinical and clinical trials and pave the way to a more personalized treatment to the benefit of the patients.

10 March 2008 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
AÁAna Rita Álvaro
Ana Rita Álvaro
JMJoão Martins
João Martins
Inês AraújoInês Araújo
Inês Araújo
JRJoana Rosmaninho‐Salgado
Joana Rosmaninho‐Salgado
António Francisco AmbrósioAntónio Francisco Ambrósio
António Francisco Ambrósio
CCCláudia Cavadas
Cláudia Cavadas
Neuropeptide Y (NPY) is a 36 amino acid peptide widely present in the CNS, including the retina. Previous studies have demonstrated that NPY promotes cell proliferation of rat post‐natal hippocampal and olfactory epithelium precursor cells. The aim of this work was to investigate the role of NPY on cell proliferation of rat retinal neural cells. For this purpose, primary retinal cell cultures expressing NPY, and NPY Y1, Y2, Y4and Y5receptors [Álvaroet al., (2007)Neurochem. Int.,50, 757] were used. NPY (10–1000 nM) stimulated cell proliferation through the activation of NPY Y1, Y2and Y5receptors. NPY also increased the number of proliferating neuronal progenitor cells (BrdU+/nestin+cells). The intracellular mechanisms coupled to NPY receptors activation that mediate the increase in cell proliferation were also investigated. The stimulatory effect of NPY on cell proliferation was reduced byl‐nitroarginine‐methyl‐esther (l‐NAME; 500 μM), a nitric oxide synthase inhibitor, 1H‐[1,2,4]oxadiazolo‐[4, 3‐a]quinoxalin‐1‐one (ODQ; 20 μM), a soluble guanylyl cyclase inhibitor or U0126 (1 μM), an inhibitor of the extracellular signal‐regulated kinase 1/2 (ERK 1/2). In conclusion, NPY stimulates retinal neural cell proliferation, and this effect is mediated through nitric oxide–cyclic GMP and ERK 1/2 pathways.

30 December 2022 in Aging Clinical and Experimental Research
Verified
Journal Article
Open access
PDF file
CCCatarina Carvalhas-Almeida
Catarina Carvalhas-Almeida
CCCláudia Cavadas
Cláudia Cavadas
AÁAna Rita Álvaro
Ana Rita Álvaro
Throughout the course of life, there are age-related changes in sleep. Despite these normal changes, there is a high percentage of older adults that report sleep dissatisfaction with a high pervasiveness of chronic insomnia, the most common sleep disorder worldwide, with its prevalence being expected to continuously increase due to the growing rates of aging and obesity. This can have different adverse health outcomes, especially by promoting both physical and cognitive decline, which ultimately may aggravate frailty in older adults. Moreover, age-related frailty and sleep dysfunction may have a common mechanism related to the hallmarks of cellular aging. Cellular aging was categorized into nine hallmarks, such as DNA damage, telomere attrition and epigenetic changes. In the context of geriatric and chronic insomnia research, this review aims at discussing the current evidence from both animal models and human cohorts addressing the link between chronic insomnia, the hallmarks of aging and their impact on frailty. Moreover, the most recent research about the putative effect of insomnia therapeutic approaches on hallmarks of aging will be also highlighted.